Insights
Search Results
Client Highlights
1.12.26
Wilson Sonsini Advises on Juvena Therapeutics on IP Matters Related to $33.5 Million Series B
On January 12, 2026, Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, announced its $33.5 million Series B. The financing round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray. Wilson Sonsini Goodrich & Rosati advised Juvena on IP matters related to the transaction.
Client Highlights
7.02.25
Firm Advises Juvena on $650 Million Research Collaboration with Eli Lilly
On June 11, 2025, Juvena Therapeutics, Inc., a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company to discover, develop, and commercialize drug candidates that improve muscle health and body composition. Wilson Sonsini Goodrich & Rosati advised Juvena Therapeutics on the transaction.
Client Highlights
11.27.23
Firm Advises Khosla Ventures on Patent Matters Related to Vivodyne’s $38 Million Seed Financing
On November 22, 2023, Vivodyne, a biotech start-up that discovers and develops more effective drugs by testing them on lab-grown human organs, announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures. Wilson Sonsini Goodrich & Rosati advised Khosla Ventures on patent strategy matters related to the financing.